Log In
BCIQ
Print this Print this
 

Feiba NF

  Manage Alerts
Collapse Summary General Information
Company Baxalta Inc.
DescriptionNano-filtered and vapor-heated sterile human plasma fraction composed of blood-clotting proteins other than Factor VIII
Molecular Target
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentMarketed
Standard IndicationHemophilia
Indication DetailsProphylactic treatment of hemophilia A and B in patients with inhibitors
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$32,000.0M

$12,639.9M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/11/2016

$32,000.0M

$12,639.9M

0

Get a free BioCentury trial today